Real-World Research shows comparative risk for mAbs used in severe asthma patients
| CONTEXT: According to the findings of a real-world research study published in Clinical and Translational Allergy, patients receiving monoclonal antibodies (mAbs) for severe asthma should be closely monitored for potential anaphylaxis signals. Data mining of post-marketing surveillance data from the US FDA adervse even reporting system resulted in over 2000 reports of anaphylaxis between 2004 and 2020 related to the use of 5 mAbs. The study showed positive signals for anaphylaxis in 4 mAbs, with only dupilumab showing a negative signal. Interestingly the authors note that increased attention is required for mepolizumab, which had almost no reports of anaphylaxis. Clearly the authors feel numbers like those are too good to be true. READ TIME: 2 mins  1. “Positive signals for anaphylaxis were observed for omalizumab, benralizumab, reslizumab, and mepolizumab.” 2. “Patients receiving certain monoclonal antibodies (mAbs) for asthma management should be closely monitored following treatment administration as these medications have been associated with positive anaphylaxis signals, according to the findings of a real-world study published in Clinical and Translational Allergy.” 3. “Data mining resulted in 2006 reports of anaphylaxis related to the use of 5 mAbs: benralizumab, dupilumab, mepolizumab, omalizumab, and reslizumab.” 4. “The analysis also revealed a significantly increased risk of initial or prolonged hospitalization due to anaphylaxis in patients who received benralizumab compared with omalizumab (42.86% vs. 28.92%, respectively; P=.024).” Source URL: https://www.medicalbag.com/home/news/anaphylaxis-risk-compared-for-monoclonal-antibodies-used-for-severe-asthma/ |